Director George Ng to step down at 2024 annual meeting; Board reduced to 5

Calidi Biotherapeutics, Inc.

George Ng will allow his director term to expire at the Company's 2024 annual shareholder meeting.
Board size reduced from six to five directors effective the date of the 2024 annual meeting.
Mr. Ng will continue as a strategic advisor and consultant to the Company.
Departure not due to any disagreement with Company operations, policies, or practices.

item 5.02 item 8.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

George Ng

Director

CLDI · Calidi Biotherapeutics, Inc.

Filed: August 20, 2024, 7:59 PM ET

On August 16, 2024, Mr. George Ng, a member of the Board of Directors (the “Board”) of Calidi Biotherapeutics, Inc. (the “Company”), informed the Board that, in order to focus on increasing professional commitments outside of the Company, he intends to allow the term of his Director position on the Board to expire, which expiration date is scheduled to be the date of the Company’s 2024 annual shareholder meeting.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

George Ng departed as Director at Calidi Biotherapeutics, Inc..

Action: allowed term to expire
Role: Director

Exact text from the filing

On August 16, 2024, Mr. George Ng, a member of the Board of Directors (the “Board”) of Calidi Biotherapeutics, Inc. (the “Company”), informed the Board that, in order to focus on increasing professional commitments outside of the Company, he intends to allow the term of his Director position on the Board to expire, which expiration date is scheduled to be the date of the Company’s 2024 annual shareholder meeting.

View on SEC.gov

Calidi Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-033215

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.